Compare Stocks: UTMD, QDEL, CERS, and EMBC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERS Cerus	$2.31 -3.3%	$2.53	$1.38 ▼ $3.47	$465.52M	1.83	2.13 million shs	1.63 million shs
EMBC Embecta	$6.86 +2.7%	$5.55	$2.77 ▼ $14.91	$388.69M	0.84	1.49 million shs	921,989 shs
QDEL QuidelOrtho	$13.48 -4.3%	$12.85	$9.92 ▼ $35.58	$924.39M	0.79	1.77 million shs	1.64 million shs
UTMD Utah Medical Products	$75.06 +0.5%	$72.91	$53.66 ▼ $76.89	$238.69M	0.38	21,773 shs	70,417 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERS Cerus	+3.46%	+6.70%	-6.64%	-16.72%	+45.73%
EMBC Embecta	+4.05%	+8.09%	+26.04%	+105.54%	-53.29%
QDEL QuidelOrtho	-0.91%	+1.51%	+29.65%	-15.08%	-52.80%
UTMD Utah Medical Products	-0.47%	-0.09%	+0.32%	+16.42%	+23.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERS Cerus	$2.31 -3.3%	$2.53	$1.38 ▼ $3.47	$465.52M	1.83	2.13 million shs	1.63 million shs
EMBC Embecta	$6.86 +2.7%	$5.55	$2.77 ▼ $14.91	$388.69M	0.84	1.49 million shs	921,989 shs
QDEL QuidelOrtho	$13.48 -4.3%	$12.85	$9.92 ▼ $35.58	$924.39M	0.79	1.77 million shs	1.64 million shs
UTMD Utah Medical Products	$75.06 +0.5%	$72.91	$53.66 ▼ $76.89	$238.69M	0.38	21,773 shs	70,417 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERS Cerus	+3.46%	+6.70%	-6.64%	-16.72%	+45.73%
EMBC Embecta	+4.05%	+8.09%	+26.04%	+105.54%	-53.29%
QDEL QuidelOrtho	-0.91%	+1.51%	+29.65%	-15.08%	-52.80%
UTMD Utah Medical Products	-0.47%	-0.09%	+0.32%	+16.42%	+23.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERS Cerus	2.40	Hold	$5.25	127.27% Upside
EMBC Embecta	1.60	Reduce	$11.00	60.35% Upside
QDEL QuidelOrtho	1.67	Reduce	$13.63	1.08% Upside
UTMD Utah Medical Products	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest UTMD, QDEL, CERS, and EMBC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	QDEL QuidelOrtho	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/9/2026	EMBC Embecta	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D) ➝ Sell (D+)
10/9/2026	QDEL QuidelOrtho	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
9/14/2026	CERS Cerus	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/9/2026	UTMD Utah Medical Products	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
8/26/2026	UTMD Utah Medical Products	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C) ➝ Hold (C-)
8/20/2026	CERS Cerus	Freedom Broker Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$6.50
8/12/2026	UTMD Utah Medical Products	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
8/12/2026	QDEL QuidelOrtho	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
8/3/2026	EMBC Embecta	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERS Cerus	$221.55M	2.10	N/A	N/A	$0.34 per share	6.79
EMBC Embecta	$1.02B	0.38	$4.29 per share	1.60	($11.12) per share	-0.62
QDEL QuidelOrtho	$2.67B	0.35	$17.97 per share	0.75	$28.27 per share	0.48
UTMD Utah Medical Products	$38.52M	6.20	$4.46 per share	16.83	$37.23 per share	2.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERS Cerus	-$15.63M	-$0.03	N/A	N/A	N/A	-3.06%	-10.19%	-3.14%	11/2/2026 (Confirmed)
EMBC Embecta	$95.40M	$1.48	4.64	3.90	N/A	8.59%	-19.25%	10.82%	11/24/2026 (Estimated)
QDEL QuidelOrtho	-$1.13B	-$15.41	N/A	9.30	N/A	-39.20%	4.88%	1.63%	11/3/2026 (Estimated)
UTMD Utah Medical Products	$11.29M	$3.28	22.88	N/A	N/A	29.04%	8.74%	8.50%	10/22/2026 (Estimated)

Latest UTMD, QDEL, CERS, and EMBC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	QDEL QuidelOrtho	$0.2023	N/A	N/A	N/A	$627.83 million	N/A
11/2/2026	Q3 2026	CERS Cerus	-$0.0125	N/A	N/A	N/A	$63.25 million	N/A
10/22/2026	Q3 2026	UTMD Utah Medical Products	N/A	$0.88	N/A	$0.88	N/A	N/A
8/7/2026	Q3 2026	EMBC Embecta	$0.2658	$0.56	+$0.2942	$0.36	$254.53 million	$271.70 million
8/6/2026	Q2 2026	QDEL QuidelOrtho	-$0.0488	$0.13	+$0.1788	-$1.36	$618.72 million	$630.90 million
7/30/2026	Q2 2026	CERS Cerus	-$0.0133	-$0.01	+$0.0033	-$0.01	$62.90 million	$63.30 million
7/23/2026	Q2 2026	UTMD Utah Medical Products	N/A	$0.84	N/A	$0.84	N/A	$8.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERS Cerus	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$0.04	0.58%	N/A	2.70%	N/A
QDEL QuidelOrtho	N/A	N/A	N/A	N/A	N/A
UTMD Utah Medical Products	$1.24	1.65%	+1.71%	37.80%	3 Years

Latest UTMD, QDEL, CERS, and EMBC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/4/2026	UTMD Utah Medical Products	quarterly	$0.31	1.67%	9/17/2026	9/17/2026	10/5/2026
8/4/2026	EMBC Embecta	quarterly	$0.01	0.8%	8/27/2026	8/27/2026	9/15/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERS Cerus	0.49	1.83	1.07
EMBC Embecta	N/A	1.68	1.17
QDEL QuidelOrtho	1.43	1.39	0.76
UTMD Utah Medical Products	N/A	48.62	44.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERS Cerus	78.37%
EMBC Embecta	93.83%
QDEL QuidelOrtho	99.00%
UTMD Utah Medical Products	69.60%

Insider Ownership

Company	Insider Ownership
CERS Cerus	5.30%
EMBC Embecta	1.30%
QDEL QuidelOrtho	1.10%
UTMD Utah Medical Products	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERS Cerus	345	201.53 million	190.84 million	Optionable
EMBC Embecta	1,850	56.66 million	55.92 million	Optionable
QDEL QuidelOrtho	6,500	68.58 million	67.82 million	Optionable
UTMD Utah Medical Products	152	3.18 million	2.93 million	Not Optionable

UTMD, QDEL, CERS, and EMBC Headlines

Recent News About These Companies

Utah Medical Products, Inc.: UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026

3 hours ago | finanznachrichten.de

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026

October 22 at 9:00 AM | accessnewswire.comA

Utah Medical Products stock trades at EUR 67.00 before quarterly results

October 20 at 9:44 AM | ad-hoc-news.deA

RxSight (NASDAQ:RXST) versus Utah Medical Products (NASDAQ:UTMD) Critical Contrast

October 19 at 7:14 AM | americanbankingnews.com

Utah Medical Products extends tender offer for Utah Medical Products stock

October 15, 2026 | ad-hoc-news.deA

Utah Medical Products stock trades at EUR 66.00 ahead of results

October 8, 2026 | ad-hoc-news.deA

UTMD Trades at a Premium to the Industry: How to Play the Stock?

October 8, 2026 | zacks.com

Utah Medical Products, Inc. Extends Tender Offer

October 5, 2026 | accessnewswire.comA

Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date

September 25, 2026 | accessnewswire.comA

Utah Medical Products, Inc. (NasdaqGS:UTMD) annonce un programme de rachat d’actions portant sur 650 000 actions, soit 20,48 %, pour 48,75 millions de dollars.

September 25, 2026 | zonebourse.comZ

Utah Medical Products, Inc. (NasdaqGS:UTMD) kündigt Aktienrückkauf über 650.000 Aktien an, entsprechend 20,48 % für 48,75 Mio. USD

September 25, 2026 | de.marketscreener.comD

Utah Medical Launches Tender Offer

September 24, 2026 | finance.yahoo.com

Utah Medical Products, Inc. Commences Tender Offer

September 24, 2026 | accessnewswire.comA

Utah Medical Products Inc's Dividend Analysis

September 17, 2026 | finance.yahoo.com

Utah Medical Products launches tender offer for 20% of shares at $75

September 15, 2026 | streetinsider.com

Utah Medical Products, Inc.: UTMD Announces Self-Tender for 20% of Its Shares

September 15, 2026 | finanznachrichten.de

UTMD Announces Self-Tender for 20% of Its Shares

September 15, 2026 | accessnewswire.comA

Utah Medical Products' Femcare Buys UK-Based Orion Medical Supplies for $4.9 Million

September 1, 2026 | finance.yahoo.com

Utah Medical Products Expands Via Orion Medical Acquisition

August 31, 2026 | tipranks.com

Utah Medical Products, Inc.: Femcare Ltd Acquires Orion Medical Supplies Ltd in the UK

August 31, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

UTMD, QDEL, CERS, and EMBC Company Descriptions

Cerus NASDAQ:CERS

$2.31 -0.08 (-3.35%)

Closing price 04:00 PM Eastern

Extended Trading

$2.33 +0.02 (+0.65%)

As of 05:58 PM Eastern

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Embecta NASDAQ:EMBC

$6.86 +0.18 (+2.69%)

Closing price 04:00 PM Eastern

Extended Trading

$6.86 0.00 (0.00%)

As of 06:28 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

QuidelOrtho NASDAQ:QDEL

$13.48 -0.60 (-4.26%)

Closing price 04:00 PM Eastern

Extended Trading

$13.48 0.00 (0.00%)

As of 06:37 PM Eastern

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Utah Medical Products NASDAQ:UTMD

$75.21 +0.49 (+0.65%)

As of 04:00 PM Eastern

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UTMD, QDEL, CERS, and EMBC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UTMD, QDEL, CERS, and EMBC Earnings

Compare Dividends

Latest UTMD, QDEL, CERS, and EMBC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UTMD, QDEL, CERS, and EMBC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UTMD, QDEL, CERS, and EMBC Company Descriptions

Cerus NASDAQ:CERS

Embecta NASDAQ:EMBC

QuidelOrtho NASDAQ:QDEL

Utah Medical Products NASDAQ:UTMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools